A5027691931- Metal complexes synthesis and properties
- Crystallization and Solubility Studies
- X-ray Diffraction in Crystallography
- Ferrocene Chemistry and Applications
- Radiopharmaceutical Chemistry and Applications
- Click Chemistry and Applications
- Organometallic Complex Synthesis and Catalysis
- Cancer Research and Treatments
- Chemical Reactions and Isotopes
- Cell Adhesion Molecules Research
- Crystallography and molecular interactions
- Synthesis and Biological Evaluation
- Porphyrin and Phthalocyanine Chemistry
- Trace Elements in Health
- Lanthanide and Transition Metal Complexes
- Magnetism in coordination complexes
- Organometallic Compounds Synthesis and Characterization
- Asymmetric Hydrogenation and Catalysis
- Advanced biosensing and bioanalysis techniques
- Aquaculture disease management and microbiota
- Immunotherapy and Immune Responses
- Nanoplatforms for cancer theranostics
- Computational Drug Discovery Methods
- DNA and Nucleic Acid Chemistry
- Glycosylation and Glycoproteins Research
University of Trieste
1995-2024
Associazione Italiana Vulvodinia Onlus
2011-2016
University of Bari Aldo Moro
2005
École Polytechnique Fédérale de Lausanne
2005
Leiden University
2004
Inserm
1997
The antitumor activity of the organometallic ruthenium(II)−arene complexes, RuCl2(η6-arene)(PTA), (arene = p-cymene, toluene, benzene, benzo-15-crown-5, 1-ethylbenzene-2,3-dimethylimidazolium tetrafluoroborate, ethyl benzoate, hexamethylbenzene; PTA 1,3,5-triaza-7-phosphaadamantane), abbreviated RAPTA, has been evaluated. In vitro biological experiments demonstrate that these compounds are active toward TS/A mouse adenocarcinoma cancer cell line whereas cytotoxicity on HBL-100 human mammary...
Ruthenium anticancer drugs have attracted an increasing interest in the last 20 years and two of them entered clinical trials. Compared to platinum drugs, complexes based on ruthenium are often identified as less toxic capable overcoming resistance induced by cancer cells. These activities were attributed transportation tumour cells transferrin selective activation more reactive species reducing environment solid tumours compared healthy tissues. been almost always designed mimic...
In our Dalton Transactions Perspective article entitled, 'Metal-based antitumour drugs in the post genomic era', (Dalton Trans., 2006, 1929-1933) we discussed metal-based light of past decades research. We concluded that post-genomic era would dictate a change direction field with knowledge genome increasingly allowing protein targets to be identified and not simply assuming DNA is only relevant target drugs. Since was published new insights into mode action have emerged making some older...
We report here two novel "extended-arms" porphyrins, TetbpyPP and TedabpyPP, in which four peripheral bpy fragments are connected to the meso positions of macrocycle through flexible linkers different length hydrophilicity. describe also new, water-soluble, tetracationic conjugate [TedabpyPP{Ru([9]aneS3)Cl}4][Cl]4 (6). Compound 6 belongs series cationic Ru−porphyrin conjugates 1−5, each bearing Ru(II) half-sandwich coordination compounds, that we recently prepared as potential...
Lysozyme, especially the one obtained from hen’s egg white, continues to show new pharmacological properties. The fact that only a few of these properties can be translated into therapeutic applications is due lack suitable clinical studies. However, this cannot hide evidence emerging scientific research. This review for first time examines, point view, all relevant studies on antiviral lysozyme, analyzing its possible mechanism action and ability block viral infections and, in some cases,...
A new series of organometallic ruthenium(II)-arene compounds the type RuCl2(η6-arene)(phosphine) (phosphine = 1,3,5-triaza-7-phosphaadamantane, PTA, and 3,7-diacetly-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane, DAPTA) with different potential hydrogen-bonding functionalities on arene ligand have been prepared studied for their antitumor activity. Cell viability studies using TS/A mouse adenocarcinoma cancer cell line nontumorigenic HBL-100 human mammary line, combined uptake determinations,...
The effects of NAMI-A (imidazolium trans-imidazoledimethyl sulfoxide-tetrachlororuthenate) are compared with cisplatin on tumor cells cultured in vitro at doses 1 to 100 microM and metastases vivo maximum tolerated doses. Using mouse tumors that metastasize the lungs, given i.p. for 6 consecutive days 35 mg/kg/day, was effective independently line being treated stage metastasis growth. Conversely, (2 mg/kg/day days) as MCa mammary carcinoma TS/A adenocarcinoma less than Lewis lung carcinoma....
The new water soluble ruthenium complexes [(C5R5)RuCl(PTA)2] (R = H, Me; PTA 1,3,5-triaza-7-phosphaadamantane) were synthesised and characterised. Their evaluation as regioselective catalysts for hydrogenation of unsaturated ketones in aqueous biphasic conditions cytotoxic agents towards the TS/A adenocarcinoma cell line is briefly presented.
The antitumour activity of the organometallic ruthenium(II)–arene mixed phosphine complexes, [Ru(η6-p-cymene)Cl(PTA)(PPh3)]BF41b and [Ru(η6-C6H5CH2CH2OH)Cl(PTA)(PPh3)]BF42b (PTA = 1,3,5-triaza-7-phosphaadamantane), have been evaluated in vitro compared to their RAPTA analogues, [Ru(η6-p-cymene)Cl2(PTA)] 1a [Ru(η6-C6H5CH2CH2OH)Cl2(PTA)] 2a. results show that addition PPh3 ligand 2a increases cytotoxicity towards TS/A adenocarcinoma cancer cells, which correlates with increased uptake, but...
NAMI-A is a ruthenium-based compound with selective anti-metastasis activity in experimental models of solid tumours. We studied whether this was dependent on anti-angiogenic ability NAMI-A. thus investigated its vitro effects endothelial cell functions necessary for angiogenesis to develop, as well vivo the chick embryo chorioallantoic membrane model. Endothelial proliferation, chemotaxis, and secretion matrix-degrading enzyme metalloproteinase-2 were inhibited by dose-dependent manner,...
Abstract New half‐sandwich Ru II ‐[9]aneS 3 complexes ([9]aneS = 1,4,7‐trithiacyclononane), namely [RuCl 2 (PTA)([9]aneS )] ( 4 ), [RuCl(PTA) )][OTf] 5 [RuCl(en)([9]aneS 6 [RuCl(enac)([9]aneS 7 [RuCl(bipy)([9]aneS 8 and [Ru(dmso‐S)(bipy)([9]aneS 9 ) [PTA 1,3,5‐triaza‐7‐phosphaadamantane; enac 1,2‐bis(isopropyleneimino)ethane; OTf CF SO – ] were prepared from Ru‐[9]aneS –dmso precursors structurally characterized, both in solution the solid state by X‐ray crystallography. Some of them are...
Ruthenium compounds have gained large interest for their potential application as chemotherapeutic agents, and in particular the complexes of type (X)[trans-RuCl4(dmso-S)L] (X = HL or Na, NAMI-A NAMI, respectively, L imidazole) are under investigation antimetastatic properties. The NAMI(-A)-like prodrugs that hydrolyze vivo, hydrolytic properties is therefore important determining nature active species. NAMI-A-type Ru(III) complex 1, (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)] (dmtp...